At EditCo, our journey began within the pioneering gene editing landscape of Synthego, where, for the past 5 years, we’ve honed our expertise and contributed to the gene editing revolution. Our experience has solidified our understanding of the indispensable role that high-quality, readily available reagents have in propelling scientific breakthroughs.

CRISPR technology stands at the forefront of discovery research, bridging the gap between fundamental biological insights and their application in addressing real-world challenges. Leveraging our proprietary automated workflows, we’ve minimized cell functionality and performance variability, enabling researchers to confidently achieve groundbreaking discoveries. Embarking on a bold and innovative path, we introduce our vision of Cells as Reagents – a transformative approach that redefines the accessibility and utility of engineered cells in research. By applying the principles of convenience, quality, and swift delivery traditionally associated with reagents, we aim to revolutionize the application of engineered cells, ensuring they are as dependable and reproducible as any standard laboratory reagent.

This visionary shift is not just a change in our product offerings but a reimagining of how scientific research is conducted. We are committed to empowering the scientific community with tools that accelerate the pace of discovery and open new avenues for innovation.

With its technologies cited in hundreds of peer-reviewed publications and utilized by thousands of commercial and academic researchers and therapeutic drug developers, Synthego is at the forefront of innovation enabling the next generation of medicines by delivering genome editing at an unprecedented scale.